Pembrolizumab for Patients with Metastatic Non-Small Cell Lung Cancer
On October 2, the Food and Drug Administration (FDA) granted accelerated approval for pembrolizumab (Keytruda®) to treat patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express a protein called PD-L1 and whose cancers progressed after platinum-based chemotherapy. Pembrolizumab targets a protein on immune cells called PD-1, one of a family of so-called checkpoint […]
Pembrolizumab for Patients with Metastatic Non-Small Cell Lung Cancer Read More »
